Protective effect of NSAIDs on cancer and influence of COX-2 C-765G genotype

Current Cancer Drug Targets

Volumn 8, Issue 8, 2008, Pages 753-764

  Siemes, C ^a   Visser, L E ^a   Coebergh, J W W ^a   Hofman, A ^a   Uitterlinden, A G ^a   Stricker, B H Ch ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti inflammatory agents; Cohort study MeSH ; Cyclooxygenase 2 (inhibitors) MeSH ; Neoplasms MeSH ; Non steroidal MeSH ; Polymorphism; Single nucleotide MeSH

Indexed keywords

ACETYLSALICYLIC ACID; ARTHROTEC; AZAPROPAZONE; CARBASALATE CALCIUM; CELECOXIB; CYCLOOXYGENASE 2; DEXKETOPROFEN; DICLOFENAC; DIFLUNISAL; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; TOLMETIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; DRUG USE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASE SEQUENCE; COHORT STUDIES; CYCLOOXYGENASE 2; DNA PRIMERS; GENOTYPE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 57449105091     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908786733414     Document Type: Article

References (49)

1. Tuynman, J. B.; Peppelenbosch, M. P.; Richel, D. J. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit. Rev. Oncol. Hematol. 2004, 52(2), 81-101.
2. Bertagnolli, M. M. The potential of non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. J. Surg. Oncol. 2003, 84(3), 113-119.
3. Lichtenberger, L. M. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol. 2001, 61(6), 631-637.
4. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 1992, 52(20), 5575-5589.
5. Waddell, W. R.; Loughry, R. W. Sulindac for polyposis of the colon. J. Surg. Oncol. 1983, 24(1), 83-87.
6. Rosenberg, L.; Palmer, J. R.; Zauber, A. G.; Warshauer, M. E.; Stolley, P. D.; Shapiro, S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst. 1991, 83(5), 355-358.
7. Smalley, W.; Ray, W. A.; Daugherty, J.; Griffin, M. R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch. Int. Med. 1999, 159(2), 161-166.
8. Thun, M. J.; Namboodiri, M. M.; Calle, E. E.; Flanders, W. D.; Heath, C. W., Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53(6), 1322-1327.
9. Peleg, I. I.; Lubin, M. F.; Cotsonis, G. A.; Clark, W. S.; Wilcox, C. M. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig. Dis. Sci. 1996, 41(7), 1319-1326.
10. Chan, A. T.; Giovannucci, E. L.; Meyerhardt, J. A.; Schernhammer, E. S.; Curhan, G. C.; Fuchs, C. S. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005, 294(8), 914-923.
11. Garcia-Rodriguez, L. A.; Huerta-Alvarez, C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin non-steroidal antiinflammatory drugs. Epidemiology 2001, 12(1), 88-93.
12. Sorensen, H. T.; Friis, S.; Norgard, B.; Mellemkjaer, L.; Blot, W. J.; McLaughlin, J. K.; Ekbom, A.; Baron, J. A. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br. J. Cancer 2003, 88(11), 1687-1692.
13. Giovannucci, E.; Rimm, E. B.; Stampfer, M. J.; Colditz, G. A.; Ascherio, A.; Willett, W. C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Int. Med. 1994, 121(4), 241-246.
14. Giovannucci, E.; Egan, K. M.; Hunter, D. J.; Stampfer, M. J.; Colditz, G. A.; Willett, W. C.; Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 1995, 333(10), 609-614.
15. Gonzalez-Perez, A.; Garcia Rodriguez, L. A.; Lopez-Ridaura, R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003, 3, 28.
16. Piazuelo, E.; Jimenez, P.; Lanas, A. COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Curr. Pharm. Des. 2003, 9(27), 2267-2280.
17. Menezes, R. J.; Huber, K. R.; Mahoney, M. C.; Moysich, K. B. Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2002, 2, 18.
18. Davies, G. L. Cyclooxygenase-2 and chemoprevention of breast cancer. J. Steroid Biochem. Mol. Biol. 2003, 86(3-5), 495-499.
19. Moorman, P. G.; Grubber, J. M.; Millikan, R. C.; Newman, B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003, 14(10), 915-922.
20. Sabichi, A. L.; Lippman, S. M. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin. Oncol. 2004, 31(2 Suppl 7), 36-44.
21. Jacobs, E. J.; Rodriguez, C.; Mondul, A. M.; Connell, C. J.; Henley, S. J.; Calle, E. E.; Thun, M. J. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl. Cancer Inst. 2005, 97(13), 975-980.
22. Papafili, A.; Hill, M. R.; Brull, D. J.; McAnulty, R. J.; Marshall, R. P.; Humphries, S. E.; Laurent, G. J. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 2002, 22(10), 1631-1636.
23. Hofman, A.; Breteler, M. M.; van Duijn, C. M.; Krestin, G. P.; Pols, H. A.; Stricker, B. H.; Thiemeier, H.; Uitterlinden, A. G.; Vingerling, J. R.; Witteman, J. C. The Rotterdam Study: objectives and design update. Eur. J. Epidemiol. 2007, 22(11), 819-829.
24. Klipstein-Grobusch, K.; den Breeijen, J. H.; Goldbohm, R. A.; Geleijnse, J. M.; Hofman, A.; Grobbee, D. E.; Witteman, J. C. Dietary assessment in the elderly: validation of a semiquantitative food frequency questionnaire. Eur. J. Clin. Nutr. 1998, 52(8), 588-596.
25. WHO. Collaborating Centre for Drug Statistics Methodology. 2006.
26. Clayton, D. M. H. Time-varying explanatory variables. In: Statistical Models in Epidemiology; Oxford University Press: Oxford, England, 1993. pp. 307-318.
27. Horton, N. J.; Laird, N. M. Maximum likelihood analysis of generalized linear models with missing covariates. Stat. Methods Med. Res. 1999, 8(1), 37-50.
28. Hosmer, D. W.; Lemeshow, S. Confidence interval estimation of interaction. Epidemiology 1992, 3(5), 452-456.
29. Andersson, T.; Alfredsson, L.; Kallberg, H.; Zdravkovic, S.; Ahlbom, A. Calculating measures of biological interaction. Eur. J. Epidemiol. 2005, 20(7), 575-579.
30. Harris, R. E.; Chlebowski, R. T.; Jackson, R. D.; Frid, D. J.; Ascenseo, J. L.; Anderson, G.; Loar, A.; Rodabough, R. J.; White, E.; McTiernan, A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003, 63(18), 6096-6101.
31. Harris, R. E.; Beebe-Donk, J.; Alshafie, G. A. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006, 6, 27.
32. Terry, M. B.; Gammon, M. D.; Zhang, F. F.; Tawfik, H.; Teitelbaum, S. L.; Britton, J. A.; Subbaramaiah, K.; Dannenberg, A. J.; Neugut, A. I. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004, 291(20), 2433-2440.
33. Project TCGA. Virtual Northern Tissue gene expression. 2006.
34. Campa, D.; Zienolddiny, S.; Maggini, V.; Skaug, V.; Haugen, A.; Canzian, F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004, 25(2), 229-235.
35. Cox, D. G.; Pontes, C.; Guino, E.; Navarro, M.; Osorio, A.; Canzian, F.; Moreno, V. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br. J. Cancer 2004, 91(2), 339-343.
36. Koh, W. P.; Yuan, J. M.; van den Berg, D.; Lee, H. P.; Yu, M. C. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br. J. Cancer 2004, 90(9), 1760-1764.
37. Wiesner, G. L.; Platzer, P.; Buxbaum, S.; Lewis, S.; MacMillen, M.; Olechnowicz, J.; Willis, J.; Chakravarti, A.; Elston, R. C.; Markowitz, S. D. Testing for colon neoplasia susceptibility variants at the human COX2 locus. J. Natl. Cancer Inst. 2001, 93(8), 635-639.
38. Ulrich, C. M.; Whitton, J.; Yu, J. H.; Sibert, J.; Sparks, R.; Potter, J. D.; Bigler, J. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol. Biomarkers Prev. 2005, 14(3), 616-619.
39. Zhan, J.; Liu, J. P.; Zhu, Z. H.; Yao, H. R.; Chen, C. Y. Relationship between COX-2 expression and clinicopathological features of colorectal cancers. Chin. Med. J. (Engl) 2004, 117(8), 1151-1154.
40. Sanak, M.; Szczeklik, W.; Szczeklik, A. Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J. Allergy Clin. Immunol. 2005, 116(1), 221-223.
41. Ali, I. U.; Luke, B. T.; Dean, M.; Greenwald, P. Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br. J. Cancer 2005, 93(8), 953-959.
42. Panguluri, R. C.; Long, L. O.; Chen, W.; Wang, S.; Coulibaly, A.; Ukoli, F.; Jackson, A.; Weinrich, S.; Ahaghotu, C.; Isaacs, W.; Kittles, R. A. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004, 25(6), 961-966.
43. Shahedi, K.; Lindstrom, S.; Zheng, S. L.; Wiklund, F.; Adolfsson, J.; Sun, J.; Augustsson-Balter, K.; Chang, B. L.; Adami, H. O.; Liu, W.; Gronberg, H.; Xu, J. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int. J. Cancer 2006, 119(3), 668-672.
44. Vogel, U.; Christensen, J.; Wallin, H.; Friis, S.; Nexo, B. A.; Raaschou-Nielsen, O.; Overvad, K.; Tjonneland, A. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat. Res. 2008, 639(1-2), 89-100.
45. Zhang, X.; Miao, X.; Tan, W.; Ning, B.; Liu, Z.; Hong, Y.; Song, W.; Guo, Y.; Shen, Y.; Qiang, B.; Kadlubar, F. F.; Lin, D. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005, 129(2), 565-576.
46. Ridker, P. M.; Cushman, M.; Stampfer, M. J.; Tracy, R. P.; Hennekens, C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997, 336(14), 973-979.
47. Waskewich, C.; Blumenthal, R. D.; Li, H.; Stein, R.; Goldenberg, D. M.; Burton, J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002, 62(7), 2029-2033.
48. Masferrer, J. L.; Leahy, K. M.; Koki, A. T.; Zweifel, B. S.; Settle, S. L.; Woerner, B. M.; Edwards, D. A.; Flickinger, A. G.; Moore, R. J.; Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60(5), 1306-1311.
49. Slattery, M. L.; Samowitz, W.; Hoffman, M.; Ma, K. N.; Levin, T. R.; Neuhausen, S. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol. Biomarkers Prev. 2004, 13(4), 538-545.